All the M42 news from Arab Health 2025

UAE-based global healthcare group M42 used the Arab Health 2025 to share quite a few news regarding its business and the business of its subsidiaries. Here's what you need to know:

M42 partnered with Rhapsody to enhance global health outcomes with Microsoft Azure

The collaboration of the two companies, powered by Microsoft Azure, aims to redefine healthcare data integration and enhance global health outcomes by delivering cutting-edge solutions for seamless and scalable interoperability.

By addressing the demand for streamlined and interoperable systems, the new partnership, Rhapsody Envoy Edge by M42, will leverage the robust infrastructure of Microsoft Azure, enabling broader access and scalability for healthcare organizations worldwide. Its innovative solutions will empower healthcare providers to exchange data effortlessly, enhance patient outcomes, and drive operational efficiency. The platform will soon be available on the Microsoft Azure Marketplace.

Key highlights of the partnership include improving healthcare interoperability by combining M42's deep expertise in healthcare and life sciences with Rhapsody's best-in-class healthcare integration knowledge and capabilities. This collaboration will simplify data exchange, optimize workflows and enable healthcare systems to focus on patient care.

M42's Imperial College London Diabetes Centre (ICLDC) signed 2 technology agreements

The first agreement is with healthcare technology solutions provider Medtronic. ICLDC currently cares for more than 1,000 patients in Abu Dhabi on Medtronic's CareLink platform. Under the new agreement, it will migrate to Medtronic's advanced CareConnect and GALAXY platforms, which offer multiple additional features.

CareConnect offers a user-friendly digital interface, designed as a more patient-centric alternative to the data-intensive CareLink dashboard. With customizable notifications, caregivers can stay promptly informed of critical events, such as abnormal glucose levels or device malfunctions. As an integrated remote patient monitoring system, CareConnect streamlines the patient care pathway by enhancing follow-up care and reducing the need for in-person clinical visits. By leveraging clinical insights alongside patient data, the platform prioritizes cases based on urgency, ensuring timely interventions when additional care is needed. Physicians can manage patients remotely through a tailored communications channel, while patients benefit from access to consistent care and comprehensive remote monitoring.

The platform also empowers care partners by enabling real-time data sharing and sending alerts directly to mobile devices. This fosters greater engagement from family members and caregivers, reducing response times to device alerts and facilitating quicker action. These features are especially crucial for managing time-sensitive conditions such as diabetes.

To address the challenges of managing diverse technological solutions, ICLDC is also collaborating with an innovative healthcare platform, Karaz, to streamline data integration. Currently, caregivers often need to check multiple software platforms to access data from various insulin and continuous glucose monitoring (CGM) devices. The Karaz platform will consolidate patient data into a single dashboard, simplifying caregivers' workflow and improving efficiency.

By emphasizing predictive modeling and data interpretation to identify trends and anticipate patient needs, its intuitive interface empowers patients to actively participate in their health management. The platform integrates predictive insights from Karaz with GALAXY's clinical analytics, enabling healthcare providers to gain a more comprehensive understanding of patient health.

M42's Danat Al Emarat Hospital for Women & Children partners with ProFaM to offer advanced reproductive health services

The partnership with UK-based ProFaM was established to perform innovative ovarian tissue cryopreservation (OTC), empowering women with the means to preserve their fertility or delay menopause naturally.

The OTC process involves freezing a small piece of ovarian tissue, ideally before the age of 35. This tissue can later be re-implanted during perimenopause to maintain hormonal balance and postpone menopause and its effects. If required, it can also preserve fertility.

Unlike egg freezing, which requires hormone stimulation and an in vitro fertilization (IVF) treatment cycle, OTC is minimally invasive and can be performed as a short day-patient procedure. This approach also offers hope to women undergoing cancer treatments and those with endometriosis or other benign conditions. It also helps those seeking to postpone menopause naturally or as an alternative to hormone replacement therapy (HRT).

The project is set to launch in the first half of this year. Initially offered as an elective service, OTC will also be integrated into laparoscopic procedures, such as surgeries for endometriosis. Abu Dhabi Biobank is a key partner for this engagement, which will receive the ovarian tissue and cryogenically store them at -196°C in its state-of-the-art laboratories. The preserved ovarian samples will be provided back to the Danat Al Emarat Hospital physicians, as required, to support the patient's own hormonal therapy journey for a period of up to 15 years.

M42 launches new structure

Lastly, as previously mentioned, M42 has officially unveiled its new structure, comprising three core platforms focusing on treatment services, AI-powered solutions, and cutting-edge healthcare technologies.

Safeya Almqtri, Deputy Group Chief Operating Officer at M42, said that M42 continues to enhance its advanced healthcare services by establishing affiliated medical centres and clinics at Sheikh Sultan bin Zayed Hospital in Sharjah, including the Imperial Diabetes Centre, Healthpoint Hospital, Amana Healthcare, and Mubadala Health.

💡Did you know?

You can take your DHArab experience to the next level with our Premium Membership.
👉 Click here to learn more